Cereno Scientific announces extended patent protection in Europe for CS585 program
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a patent has been approved (Notice of Allowance) in the first patent family for the preclinical Prostacyclin Receptor Agonist program, which includes drug candidate CS585. The patent expands the patent protection for the Prostacyclin Receptor Agonist program to also include Europe, one of the largest markets for cardiovascular disease.
“I am pleased to announce the second patent in Europe for our preclinical Prostacyclin Receptor Agonist program, an important milestone that expands the patent protection of the program in an important market. We continue to secure a strong patent protection for our preclinical programs to support a favorable commercial positioning in future treatments for cardiovascular diseases”, said Sten R. Sörensen, CEO, Cereno Scientific.
The first patent family is titled “Hydroxyeicosatrienoic acid compounds and their use as therapeutic agents”. The official approval of the patent rights will be implemented after payment of an administrative fee. The preclinical Prostacyclin Receptor Agonist program, developed in collaboration with University of Michigan, has previously obtained patents in the US for the first patent family and in the US and Europe for the second patent family. Based on these, there are valid patents protecting the CS585 program through 2039.
About CS585
CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The drug candidate CS585 has not yet been assigned a specific indication for clinical development as evaluation in the preclinical program is still ongoing.
In April 2023 Cereno announced that the Company signed a license agreement for the drug candidate CS585 with the University of Michigan. The agreement provides Cereno the exclusive rights to CS585 for further clinical development and commercialization.
In early November 2023, CS585 was highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding.
For further information, please contact:
Henrik Westdahl, Director IR & Communications
Email: henrik.westdahl@cerenoscientific.com
Phone: +46 70-817 59 96
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.